证 券 研 究 报 告 行业周报 医药供给端变量增加 医药行业周报 投资评级： 报告日期： 推荐 （ 维持 ） 2026年03月01日 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 1.供给端变量增加，提价范围进一步扩大 受反内卷、两用物项管理、反倾销等一系列政策影响，医药供给端变量增加，促进价格周期的转变。首先原料药产业供给 端变化最为敏感，青霉素产业链已开始价格的反弹。2026年1月末，印度商工部外贸总局（DGFT）发布对青霉素工业盐、 6-APA和阿莫西林的进口限价，其中6-APA限价为3405 印度卢比/公斤，截止日期至 2027-01-28。按照印度的限价标准，6- APA折合人民币约260元/kg，高于目前出口报价，国内企业已开始逐步提高报价。2月25日起星湖伊品计划对赖氨酸、苏氨 酸及小品种氨基酸上调50-300元/吨，同日，象屿生化苏氨酸报价上调300元/吨。从产能供给来看，包括赖氨酸、苏氨酸和 蛋氨酸在内的饲用氨基酸添加剂供给都过剩，但2025年下半年以来价格普遍处于低位，行业开工率普遍不足，产量的 ...

证券代码：000739 证券简称：普洛药业 公告编号：2026-07 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2026 年 2 月 3 日，普洛药业股份有限公司（以下简称"公司"）与招商 银行股份有限公司金华义乌支行（"招商银行"）签订《不可撤销担保书》（合 同编号：571HT260202T00092801）,同意为公司全资子公司浙江普洛家园药业有 限公司（以下简称"家园药业"）与招商银行签署的《借款合同》（合同编号： 571HT260202T000928）提供流动资金借款 2,000 万元连带责任保证，担保期限为 12 个月。 2、2026 年 2 月 4 日，公司与招商银行签订《不可撤销担保书》（合同编号： 571HT260203T00179801）,同意为公司全资子公司家园药业与招商银行签署的《借 款合同》（合同编号：571HT260203T001798）提供流动资金借款 1,000 万元连带 责任保证，担保期限为 12 个月。 四、被担保子公司基本情况介绍 （一）被担保人 ...

机器学习因子选股月报（2026 年 3 月） 截至 2026年 2月 25日，2月当期多头组合超额收益最高的五个行业（除综合） 分别为石油石化、通信、电子、有色金属、计算机，多头组合相对行业指数超 额收益分别为 7.91%、3.11%、3.06%、2.78%以及 2.78%。 近一年来看，多头组合月平均超额收益最高的五个行业（除综合）分别为房地 产、商贸零售、汽车、建筑、消费者服务，超额收益分别为 3.83%、2.04%、 1.93%、1.50%以及 1.49%。且 29个中信一级行业（除综合）中， GAN_GRU 因子多头组合近一年有 7个行业未跑赢对应中信一级行业指数（交通运输、建 材、煤炭、非银金融、传媒、有色、通信）。 摘要 西南证券研究院 [Table_Author] 分析师：郑琳琳 执业证号：S1250522110001 邮箱：zhengll@swsc.com.cn 分析师：祝晨宇 执业证号：S1250525100004 邮箱：zhcy@swsc.com.cn [Table_ReportInfo] 2026 年 02 月 26 日 证券研究报告•金融工程报告 机器学习金融工程月报 相关研究 请务必 ...

[Table_ReportInfo] 2026 年 02 月 26 日 证券研究报告•金融工程报告 机器学习金融工程月报 机器学习因子选股月报（2026 年 3 月） 截至 2026年 2月 25日，2月当期多头组合超额收益最高的五个行业（除综合） 分别为石油石化、通信、电子、有色金属、计算机，多头组合相对行业指数超 额收益分别为 7.91%、3.11%、3.06%、2.78%以及 2.78%。 [Table_Summary] GAN_GRU 因子：基于前期报告《量价时序特征挖掘模型在深度学习因子中 的应用》（2024年 7月 11日）中提到的 GAN_GRU模型，定期更新 GAN_GRU 因子自 2024年以来表现情况。其中 GAN_GRU因子为利用生成式对抗神经网 络 GAN 模型进行量价时序特征处理后再利用 GRU 模型进行时序特征编码得 到的选股因子。 表现跟踪：自 2019 年 2月至 2026 年 2月，月频调仓的基础上，GAN_GRU 因子在全 A 范围内 IC均值 0.1096***，多头组合年化超额收益率 22.32%；截 至 2026年 2月 25日，GAN_GRU 最新一期 IC为-0. ...

Investment Rating - The industry investment rating is "Overweight (Maintain)" [4] Core Insights - The recent results of the national centralized procurement for batches 1-8 have been released, which is expected to benefit leading companies with scale effects, particularly those integrated in raw material and formulation production [6] - The procurement process involved 5.1 million medical institutions and 1,091 domestic and foreign companies, with 4,163 products selected from 1,020 companies, indicating a high participation rate and a stable supply of selected products [6] - The procurement cycle is set to last until the end of 2028, allowing selected companies to secure a three-year national market, which is beneficial for capacity planning and cost optimization [6] Summary by Sections Industry Overview - The industry comprises 502 listed companies with a total market value of 73,023.15 billion yuan and a circulating market value of 67,026.08 billion yuan [2] Procurement Results - The procurement covers 316 commonly used drugs across 26 therapeutic areas, with a high selection rate of 93% for participating companies [6] - The average number of selected companies per product is 14, ensuring a diverse supply base and rich clinical choices [6] Competitive Landscape - The procurement reflects a shift in policy from "price reduction and expansion" to "price stability and quality assurance," favoring leading companies with compliance capabilities and scale advantages [6] - Companies like Huahai Pharmaceutical and Kelun Pharmaceutical have significant advantages in their respective fields, with high selection rates for major products [6] Future Outlook - The procurement process is expected to stabilize prices and industry expectations, moving the focus from "lowest price competition" to a comprehensive competition based on quality, capacity, compliance, and brand [6] - The new requirements for production experience and compliance are likely to accelerate the exit of smaller, weaker companies from the market [6]

Summary of Industry Reports Industry: Pharmaceutical and Biotechnology Key Points from Document 1 1. **Raw Material Supply Changes**: The supply of raw materials is accelerating, with a focus on subsequent volume and price changes [1] 2. **Global GLP-1 Landscape**: The global GLP-1 landscape is continuously evolving, and Chinese companies are still pursuing international expansion [1] 3. **Small Nucleic Acid Sector**: Leading companies are gradually entering the small nucleic acid field, with market progress expected to drive the development of supporting industrial chains [1] 4. **Retail Pharmaceutical Market Outlook**: The retail pharmaceutical market is expected to improve by Q4 2025, with an enhanced positioning of chain pharmacies [1] 5. **Value of Oral Immunomodulatory Drugs**: Emphasis on the market value of oral immunomodulatory drugs [1] 6. **Investment Recommendations**: Recommended companies include Chuaning Biological, with attention to Lianbang Pharmaceutical, Guobang Pharmaceutical, and Puluo Pharmaceutical, as well as synthetic biology companies [1] 7. **CXO Order Trends**: Positive trends in CXO orders and rising prices for safety evaluation orders, with recommendations for Yinos and Zhaoyan New Drug, and recommendations for Weiya Biological and Puris [1] Key Points from Document 2 1. **Small Nucleic Acids Breakthrough**: Continuous breakthroughs in small nucleic acids, with ongoing progress in external authorizations by Chinese companies, recommending Yuekang Pharmaceutical and Sunshine Novo [2] 2. **Self-Immunity Field**: Focus on breakthroughs in oral directions and difficult-to-treat areas like UC/IBD, recommending Yahong Pharmaceutical and Yifang Biological [2] 3. **GLP-1 Weight Loss Authorizations**: Recommendations for Zhongsheng Pharmaceutical in the GLP-1 weight loss field, with attention to Lianbang Pharmaceutical and Shiyao Group [2] 4. **ZAP-X Radiation Therapy Equipment**: Initiation of domestic clinical research for ZAP-X radiation therapy equipment, recommending Baiyang Pharmaceutical [2] 5. **Policy Support for Brain-Computer Interface Technology**: Support for the development of invasive brain-computer interfaces, recommending Meihao Medical and Botuo Biological, with accelerated approvals for non-invasive devices, focusing on Xiangyu Medical and Kefu Medical [2] 6. **High-Value Medical Device Exports**: Breakthroughs in exports of high-value medical consumables, with attention to Chunli Medical, Aikang Medical, Nanwei Medical, and Baixin An [2] 7. **AI in Healthcare**: Accelerated applications of AI in healthcare, reshaping application scenarios and bringing changes in industrial chain value, recommending Anbiping and focusing on Yuyue Medical and Meinian Health [2] 8. **Chain Pharmacy Industry**: Industry consolidation in chain pharmacies, with policy support for enhanced positioning, recommending Yifeng Pharmacy and Laobaiqing, with attention to Yixintang [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector is experiencing a rebound in bottom assets, particularly in traditional Chinese medicine, medical services, and pharmacies, driven by market rotation and price increase expectations in raw materials [7][11] - The report emphasizes the importance of focusing on bottom assets that are expected to see turning points and well-adjusted innovative drug sectors, with a positive outlook on growth directions representing the future of the pharmaceutical industry [11] - Key themes include continuous attention to pharmaceutical and medical AI+, as well as significant data updates expected from major conferences in 2026 [11] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 3.28% compared to the Shanghai Composite's 0.29% since the beginning of 2026 [26] - The report notes that the pharmaceutical sector's valuation is currently at 22.8 times PE, with a premium of 11.7% over the overall A-share market [30] Key Company Performance - Recommended stocks for February include WuXi Biologics, Tigermed, and others, with a focus on companies that have shown significant pipeline progress or business development expectations [8][36] - The report highlights the performance of companies like Guangsheng Tang and Nuo Cheng Jian Hua, which have made notable advancements in their core pipelines [36] Industry Trends - The report discusses the trend of combining IO plus therapies and the development of new targets in the dual antibody space, indicating a growing trend in clinical applications [12][14] - Attention is drawn to the ADC (Antibody-Drug Conjugate) sector, particularly large indication FIC (First-in-Class) products and the potential for new indications to enhance overseas mapping [14][17] - The report also highlights the evolving landscape in blood cancers, with new therapies showing promise in previously underserved areas [20]

Core Viewpoint - The company has experienced rapid growth in its CDMO projects, which are now entering the commercialization phase, contributing to an increase in CDMO capacity utilization [2] Group 1: CDMO Project Growth - The number of CDMO projects has been steadily increasing in recent years [2] - The transition to commercial production is expected to enhance capacity utilization for CDMO [2] Group 2: Business Performance Insights - The CDMO projects and capacity involve multiple subsidiaries and numerous production lines, indicating that strong performance in some production lines does not fully represent the overall business situation [2] - The company advises investors to rely on disclosed announcements for accurate business performance assessments and to exercise caution in their analyses [2]

Core Viewpoint - The company has reported a significant increase in CDMO orders for Q1 2026, with a year-on-year growth of 100%, indicating strong confidence in achieving record profits in 2026 [1] Group 1: CDMO Project Growth - The company has experienced rapid growth in its CDMO projects in recent years, which are gradually entering the commercial production phase [1] - Increased utilization of CDMO capacity is expected as a result of this growth [1] Group 2: Production Capacity and Business Outlook - The CDMO projects and production capacity involve multiple subsidiaries and numerous production lines, meaning that strong performance in some production lines does not fully represent the overall business situation [1] - The company advises investors to rely on disclosed announcements for accurate performance expectations and to exercise caution in their analyses [1]